Corticosteroid-Induced Immunosuppression Ultimately Does Not Compromise the Efficacy of Antibiotherapy in Murine Mycobacterium ulcerans Infection

Local and Regional Re-Establishment of Cellular Immunity during Curative Antibiotherapy of Murine Mycobacterium ulcerans Infection

(2012) Teresa G. Martins et al.   PLoS One

Successful Outcomes with Oral Fluoroquinolones Combined with Rifampicin in the Treatment of Mycobacterium ulcerans: An Observational Cohort Study

(2012) Daniel P. O'Brien et al.   PLoS Neglected Tropical Diseases

Chemotherapy-Associated Changes of Histopathological Features of Mycobacterium ulcerans Lesions in a Buruli Ulcer Mouse Model

(2011) Marie-Thérèse Ruf et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Paradoxical Responses After Start of Antimicrobial Treatment in Mycobacterium ulcerans Infection

(2011) W. A. Nienhuis et al.   CLINICAL INFECTIOUS DISEASES

Risk Factors for Development of Paradoxical Response during Anti-Tuberculosis Treatment in HIV-Negative Patients with Pleural Tuberculosis

(2011) Jae Woo Jung et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice

(2011) Deepak Almeida et al.   PLoS Neglected Tropical Diseases

Secondary Buruli Ulcer Skin Lesions Emerging Several Months after Completion of Chemotherapy: Paradoxical Reaction or Evidence for Immune Protection?

(2011) Marie-Thérèse Ruf et al.   PLoS Neglected Tropical Diseases

Steroid-Resistant Lymphatic Remodeling in Chronically Inflamed Mouse Airways

(2010) Li-Chin Yao et al.   AMERICAN JOURNAL OF PATHOLOGY

Severe Multifocal Form of Buruli Ulcer after Streptomycin and Rifampin Treatment: Comments on Possible Dissemination Mechanisms

(2010) Ghislain Emmanuel Sopoh et al.   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment of Mycobacterium ulcerans Disease

(2010) F. S. Sarfo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Oral Treatment for Mycobacterium ulcerans Infection: Results From a Pilot Study in Benin

(2010) Annick Chauty et al.   CLINICAL INFECTIOUS DISEASES

Buruli Ulcer: Advances in Understanding Mycobacterium ulcerans Infection

(2010) Douglas S. Walsh et al.   DERMATOLOGIC CLINICS

MycobacteriumulceransTriggers T-Cell Immunity followed by Local and Regional but Not Systemic Immunosuppression

(2010) Alexandra G. Fraga et al.   INFECTION AND IMMUNITY

Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial

(2010) Willemien A Nienhuis et al.   LANCET

All-Oral Antibiotic Treatment for Buruli Ulcer: A Report of Four Patients

(2010) Claire L. Gordon et al.   PLoS Neglected Tropical Diseases

Response to Treatment in a Prospective Cohort of Patients with Large Ulcerated Lesions Suspected to Be Buruli Ulcer (Mycobacterium ulcerans Disease)

(2010) Kapay Kibadi et al.   PLoS Neglected Tropical Diseases

Phagocytosis ofMycobacterium ulceransin the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions

(2009) D. Schütte et al.   BRITISH JOURNAL OF DERMATOLOGY

Buruli ulcer

(2009) Françoise Portaels et al.   CLINICS IN DERMATOLOGY

IFN- -Dependent Activation of Macrophages during Experimental Infections by Mycobacterium ulcerans Is Impaired by the Toxin Mycolactone

(2009) E. Torrado et al.   JOURNAL OF IMMUNOLOGY

Paradoxical responses in non-HIV-infected patients with peripheral lymph node tuberculosis

(2009) Oh-Hyun Cho et al.   JOURNAL OF INFECTION

Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria

(2008) Hui Hong et al.   NATURAL PRODUCT REPORTS